IP Library › Granted Patent US 12,226,396
Granted Patent B2
US 12,226,396 · App. 18/163,321 · Granted Feb 18, 2025

Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections

Inventors: Ulf Ellervik (Löddeköpinge, SE); Olov Sterner (Malmö, SE); Helena Strevens (Lund, SE); Sophie Manner (Helsingborg, SE)
Assignee: Gedea Biotech AB
A61K31/366A61K31/191A61K31/765A61P31/04A61K9/0034A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,226,396
App. No.
18/163,321
Granted
Feb 18, 2025
Kind
B2
Abstract

Pharmaceutical compositions and methods of using said pharmaceutical compositions are provided herein. A method of preventing preterm birth in a pregnant individual is also provided, said method comprising administering to said individual a pharmaceutical composition comprising a compound of Formula XX or a lactone thereof of formula XIX or XXI and preventing said preterm birth by said administration.

Claims (17)

1. A method for preventing preterm birth in a pregnant individual with bacterial vaginosis, said method consisting of administering to said individual a pharmaceutical composition comprising a compound of Formula XX,

or a lactone thereof of formula XIX or XXI,

and

preventing said preterm birth by said administration;

wherein said pharmaceutical composition comprises at least 5 wt % of the compound of Formula XX, XIX, XXI or combination thereof, and wherein said compound of Formula XX, XIX, XXI or combination thereof are the sole antimicrobial agent in said pharmaceutical composition.

2. The method according to claim 1 , wherein the compound is of Formula XIX or Formula XX.

3. The method according to claim 1 , wherein the compound is of Formula XIX.

4. The method according to claim 1 , wherein the pharmaceutical composition comprises the compound of Formula XIX and the compound of Formula XX.

5. The method according to claim 1 , wherein the pharmaceutical composition comprises no more than 10 wt % water.

6. The method according to claim 1 , wherein the pharmaceutical composition consists of the compound of Formula XIX alone or in combination with the compound of Formula XX or the compound of Formula XXI, or both, and one or more pharmaceutically acceptable excipients.

7. The method according to claim 1 , wherein the individual is a mammal.

8. The method according to claim 7 , wherein the mammal is a human.

9. The method of claim 1 , wherein said individual has an elevated risk for preterm birth.

10. The method according to claim 1 , wherein the pharmaceutical composition is administered vaginally.

11. The method according to claim 1 , wherein said pharmaceutical composition is formulated as a tampon, vagitorium, vaginal aerosol, vaginal cup, vaginal gel, vaginal insert, vaginal patch, vaginal ring, vaginal sponge, vaginal suppository, vaginal cream, vaginal emulsion, vaginal foam, vaginal lotion, vaginal ointment, vaginal powder, vaginal shampoo, vaginal solution, vaginal spray, vaginal suspension, vaginal tablet, vaginal rod, vaginal disc, vaginal device, and any combination thereof, or wherein the pharmaceutical composition is present on a sanitary napkin, an incontinence pad or diaper, or a panty liner.

12. The method according to claim 1 , wherein said compound is administered as an oligomer or polymer.

13. The method according to claim 12 , wherein the oligomer or polymer comprises one or more compounds selected from the group consisting of gluconic acid and δ-gluconolactone.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2024
From: ELLERVIK, ULF; STERNER, OLOV; STREVENS, HELENA; MANNER, SOPHIE
To: GEDEA BIOTECH AB
Reel/Frame 068876/0746 →
Priority Claims (1)
EP 17195192 · Oct 6, 2017 · regional
Continuity (2)
Division 16753899
Related Publication 20230181523A1 · Jun 15, 2023
References Cited (42)
US 6361789B1 · Zuccato et al. · 2002 [cited by applicant]
US 7569530B1 · Pan et al. · 2009 [cited by applicant]
US 8795693B2 · Tamarkin et al. · 2014 [cited by applicant]
US 9101662B2 · Tamarkin et al. · 2015 [cited by applicant]
US 10993907B2 · Ellervik · 2021 [cited by examiner]
US 11026883B2 · Masto et al. · 2021 [cited by applicant]
US 11696891B2 · Ellervik · 2023 [cited by examiner]
US 20040126369A1 · Payne et al. · 2004 [cited by applicant]
US 20060105008A1 · Ahmad · 2006 [cited by applicant]
US 20060172007A1 · Ahmad · 2006 [cited by examiner]
US 20070059278A1 · Ahmad et al. · 2007 [cited by applicant]
US 20080058421A1 · Lopes · 2008 [cited by applicant]
AU 2012250862B2 · 2012 [cited by applicant]
CN 101305993A · 2008 [cited by applicant]
CN 102070774A · 2011 [cited by applicant]
EP 1764100 · 2007 [cited by applicant]
JP 2002138142A · 2002 [cited by applicant]
JP 20070771450 · 2007 [cited by applicant]
JP 2017501741 · 2017 [cited by applicant]
KR 101841976B1 · 2018 [cited by applicant]
WO WO200044230A1 · 2000 [cited by applicant]
WO WO2002087570A1 · 2002 [cited by applicant]
WO WO2004000016A2 · 2003 [cited by applicant]
WO WO2005105070A2 · 2005 [cited by applicant]
WO 2008108834A2 · 2008 [cited by applicant]
WO 2010129443A2 · 2010 [cited by applicant]
WO 2016141946A1 · 2016 [cited by applicant]
WO 2017174731A1 · 2017 [cited by applicant]
WO WO2019068862A1 · 2019 [cited by applicant]
WO WO2020201515A1 · 2020 [cited by applicant]
Marion Owen, Management of Vaginitis, Dec. 1, 2004, American Family Physician, vol. 70 (Year: 2004). [cited by examiner]
Mayo Clinic Staff, Preterm Labor, Feb. 8, 2022, Mayo Clinic (Year: 2022). [cited by examiner]
Roberts et al. Treatment of asymptomatic vaginal candidiasis in pregnancy to prevent preterm birth: an open label pilot randomized controlled trial, BMC Pregnancy and Childbirth 2011, 11:18 (Year: 2011). [cited by examiner]
New Food Industry, 47(3): 45-54, 2005. [cited by applicant]
Nieto-Penalver, C. et al., Gluconic acid produced by Gluconacetobacter diazotrophocus Pal5 possesses antimicrobial properties, Research in Microbiology, 165: 549-558, 2014. [cited by applicant]
English Translation of Japanese Reasons for Rejection, Japanese Application No. 2020-519028, Oct. 11, 2022. [cited by applicant]
Dujon, B. et al., Genome evolution in yeasts, Nature, Year:2004, 430, (35-44). [cited by applicant]
Gillum, A.M. et al., Isolation of the Candida Albicans Gene for orotidine-5′-phosphate Decarboxylase by Complementation of S. Cerevisiae ura3 and [cited by applicant]
Moyes, D.L. et al., Candidalysin is a fungal peptide toxin critical for mucosal infection, Nature, Year: 2016, 532, (64-68). [cited by applicant]
Sawyer, D. et al., The Lactone-Acid-Salt Equilibria for D-Glucono-do-lactone adn the Hydrolysis Kinetics for this Lactone, J. Am. Chem. Soc., Year: 1959, 81, (5302-5306). [cited by applicant]
Scherz, K. et al., Genetic Basisc for [cited by applicant]
Serrano-Fujarte, I. et al., Influence of Culture Media on Biofilm Formation by [cited by applicant]